Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN4A | P35499 | 7/20 | 1.00 |
| ▸ | SCN9A | Q15858 | 5/20 | 0.62 |
| ▸ | CA1 | P00915 | 1/20 | 0.46 |
| ▸ | CA2 | P00918 | 1/20 | 0.46 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.46 |
| ▸ | MCL1 | Q07820 | 3/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | BTK | Q06187 | 1/20 | 0.43 |
| ▸ | XDH | P47989 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3367406 | 0.88 | SCN4A (0.79) | SCN4ASCN9APARP10BTK | |
| SCHEMBL13168520 | 0.87 | SCN4A (0.77) | SCN4ASCN9ACA1CA2PARP10 | |
| SCHEMBL1384902 | 0.87 | SCN4A (1.00) | SCN4ASCN9A | |
| SCHEMBL3367212 | 0.87 | SCN4A (0.77) | SCN4ASCN9APARP10MCL1 | |
| SCHEMBL13186012 | 0.87 | SCN4A (0.77) | SCN4ASCN9ACA1CA2PARP10 | |
| SCHEMBL27795462 | 0.86 | SCN4A (0.74) | SCN4ASCN9ANPC1RAB9A | |
| SCHEMBL13186011 | 0.86 | SCN4A (0.74) | SCN4ASCN9ABTKXDH | |
| SCHEMBL13168519 | 0.86 | SCN4A (0.74) | SCN4ASCN9ACA1CA2PARP10 | |
| SCHEMBL3368650 | 0.83 | SCN4A (0.74) | SCN4ASCN9A | |
| SCHEMBL3366557 | 0.83 | SCN4A (0.71) | SCN4ASCN9APARP10RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2266960-B1 | Aryl-substituted pyrazoles, imidazoles, oxazoles, thiazoles and pyrroles as anticonvulsants | EURO CELTIQUE SA (LU) | 2014-01-22 | — | — | EP | claimed |
| JP-4832647-B2 | — | — | 2011-12-07 | — | — | JP | claimed |
| EP-2266960-A2 | Aryl-substituted pyrazoles, imidazoles, oxazoles, thiazoles and pyrroles as anticonvulsants | EURO-CELTIQUE S.A. (LU) | 2010-12-29 | — | — | EP | claimed |
| EP-1173169-A4 | ARYL SUBSTITUTED PYRAZOLES, IMIDAZOLES, OXAZOLES, THIAZOLES AND PYRROLES, AND THE USE THEREOF | EURO CELTIQUE SA (LU) | 2007-04-04 | — | — | EP | claimed |
| US-20030069292-A1 | Aryl substituted pyrazoles, imidazoles, oxazoles, thiazoles and pyrroles, and the use thereof | EURO-CELTIQUE S.A. | 2003-04-10 | — | — | US | claimed |
| JP-2002540155-A | — | — | 2002-11-26 | — | — | JP | claimed |
| US-6414011-B1 | CENTRAL NERVOUS SYSTEM DISORDERS | EURO-CELTIQUE S.A. (LU) | 2002-07-02 | — | — | US | claimed |
| CN-1353605-A | Aryl substituted pyrazoles, imidazoles, oxazoles, thiazoles and pyrroles, and use thereof | EURO CELTIQUE SA (LU) | 2002-06-12 | — | — | CN | claimed |
| EP-1173169-A1 | ARYL SUBSTITUTED PYRAZOLES, IMIDAZOLES, OXAZOLES, THIAZOLES AND PYRROLES, AND THE USE THEREOF | Euro-Celtique S.A. (LU) | 2002-01-23 | — | — | EP | claimed |
| WO-2000057877-A1 | ARYL SUBSTITUTED PYRAZOLES, IMIDAZOLES, OXAZOLES, THIAZOLES AND PYRROLES, AND THE USE THEREOF | EURO-CELTIQUE S.A. (LU) | 2000-10-05 | — | — | WO | claimed |
| EP-2266960-B1 | Aryl-substituted pyrazoles, imidazoles, oxazoles, thiazoles and pyrroles as anticonvulsants | EURO CELTIQUE SA (LU) | 2014-01-22 | — | — | EP | disclosed |
| WO-2013131872-A1 | IMAGING NEURAL ACTIVITY | GE HEALTHCARE LIMITED (GB) | 2013-09-12 | — | — | WO | disclosed |
| EP-2266960-A2 | Aryl-substituted pyrazoles, imidazoles, oxazoles, thiazoles and pyrroles as anticonvulsants | EURO-CELTIQUE S.A. (LU) | 2010-12-29 | — | — | EP | disclosed |
| EP-1173169-B1 | ARYL SUBSTITUTED PYRAZOLES, IMIDAZOLES, OXAZOLES, THIAZOLES AND PYRROLES, AND THE USE THEREOF | EURO CELTIQUE SA (LU) | 2010-05-12 | — | — | EP | disclosed |
| CN-101678127-A | Measurement of neural activity | HAMMERSMITH IMANET LTD | 2010-03-24 | — | — | CN | disclosed |
| US-20030069292-A1 | Aryl substituted pyrazoles, imidazoles, oxazoles, thiazoles and pyrroles, and the use thereof | EURO-CELTIQUE S.A. | 2003-04-10 | — | — | US | disclosed |
| US-6414011-B1 | CENTRAL NERVOUS SYSTEM DISORDERS | EURO-CELTIQUE S.A. (LU) | 2002-07-02 | — | — | US | disclosed |
| CN-1353605-A | Aryl substituted pyrazoles, imidazoles, oxazoles, thiazoles and pyrroles, and use thereof | EURO CELTIQUE SA (LU) | 2002-06-12 | — | — | CN | disclosed |
| EP-1173169-A1 | ARYL SUBSTITUTED PYRAZOLES, IMIDAZOLES, OXAZOLES, THIAZOLES AND PYRROLES, AND THE USE THEREOF | Euro-Celtique S.A. (LU) | 2002-01-23 | — | — | EP | disclosed |
| WO-2000057877-A1 | ARYL SUBSTITUTED PYRAZOLES, IMIDAZOLES, OXAZOLES, THIAZOLES AND PYRROLES, AND THE USE THEREOF | EURO-CELTIQUE S.A. (LU) | 2000-10-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030069292-A1 | Aryl substituted pyrazoles, imidazoles, oxazoles, thiazoles and pyrroles, and the use thereof | GRIK5, GRIN3A, GRIK3 | SCN4A 598/4885SCN9A 671/4885CA1 2176/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.